Sun Pharma Corporate Overview

India Business - Sales ramp-up Leadership in chronic segment; Strong positioning in acute segment 28 brands in top 300 brands of the country Sales in Rs. Billion, Therapeutic Revenue Break-up** 24 FY11 FY12 Impact of Ranbaxy Acquisition 29 29 30 37 10 year CAGR -16% One-time impact of 103 change in 97 distribution 80 77 73 71 67 FY17 © Sun Pharmaceutical Industries Limited. All Rights Reserved. Others Opthalmology 3% 4% Urology 3% Gynaecology, 3% Respiratory 4% Vitamins/ Minerals / Nutrients, 5% Cardiology 18% SUN PHARMA Dermatology, 6% Market Share 8.2% Neuro-Psychiatry 17% Pain / Analgesics 7% Anti-Infectives, 9% Diabetology 9% Gastroenterology 12% **As per AIOCD AWACS - Mar'21 24

View entire presentation